Home   Search   Browse   Statistics   User guide   FAQs   Post question   Download   Process data  
Search results for the GEO ID: GSE6400
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM147099
GPL570
Actinomycin D treated A549 human lung cancer cell cultures replicate A Actinomycin D treated A549 human lung cancer cell cultures replicate A A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147363
GPL570
Actinomycin D treated A549 human lung cancer cell cultures replicate B Actinomycin D treated A549 human lung cancer cell cultures replicate B A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147364
GPL570
Actinomycin D treated A549 human lung cancer cell cultures replicate C Actinomycin D treated A549 human lung cancer cell cultures replicate C A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147365
GPL570
Mannitol control treated A549 human lung cancer cell cultures replicate A Mannitol control treated A549 human lung cancer cell cultures replicate A A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147366
GPL570
Mannitol control treated A549 human lung cancer cell cultures replicate B Mannitol control treated A549 human lung cancer cell cultures replicate B A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147367
GPL570
Mannitol control treated A549 human lung cancer cell cultures replicate C Mannitol control treated A549 human lung cancer cell cultures replicate C A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147368
GPL570
1.25uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate A 1.25uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate A A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 1.25uM sapphyrin PCI-2050 (1.25uM final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 1.25uM sapphyrin PCI-2050 (1.25uM final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147369
GPL570
1.25uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate B 1.25uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate B A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 1.25uM sapphyrin PCI-2050 (1.25uM final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 1.25uM sapphyrin PCI-2050 (1.25uM final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147370
GPL570
1.25uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate C 1.25uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate C A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 1.25uM sapphyrin PCI-2050 (1.25uM final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 1.25uM sapphyrin PCI-2050 (1.25uM final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147520
GPL570
2.5uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate A 2.5uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate A A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 2.5uM sapphyrin PCI-2050 (final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 2.5uM sapphyrin PCI-2050 (final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147521
GPL570
2.5uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate B 2.5uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate B A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 2.5uM sapphyrin PCI-2050 (final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 2.5uM sapphyrin PCI-2050 (final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM147522
GPL570
2.5uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate C 2.5uM sapphyrin PCI-2050 treated A549 human lung cancer cell cultures replicate C A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 2.5uM sapphyrin PCI-2050 (final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1X10^5 per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, 2.5uM sapphyrin PCI-2050 (final concentration) was added to the culture. After incubation for four hours, the culture was washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes